We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.005 | 0.11% | 4.65 | 4.41 | 4.89 | 4.53 | 4.51 | 4.53 | 241,784 | 16:35:17 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.51 | 9.35M |
Date | Subject | Author | Discuss |
---|---|---|---|
22/7/2020 15:16 | Same. Could I have a coin please?Craigy | craigy | |
22/7/2020 14:49 | Could I have one as well please | morrie1234 | |
22/7/2020 14:47 | Me too please | stepaside | |
22/7/2020 14:45 | Coin me too please | elsa7878 | |
22/7/2020 14:42 | Hello Nobby - me too please.. D | bignads | |
22/7/2020 14:40 | Hello Nobby May I have coins to join the thread please. TiA | adg | |
22/7/2020 14:39 | Leonard Licht has sold 2 million shares. He had 9.7 million. He bought most in 2018 at around 15-20p so who can begrudge him as he has made 10X. Polar Capital always had 6.95% stake so no idea why it was re-announced yesterday. | elsa7878 | |
22/7/2020 14:36 | Really recommend that people watch the Dr John Campbell video mentioned by tickboo - Great summary of the science - helps people to understand how this drug treatment works and its applicability to Covid and influenza viruses. Huge treatment potential. Will rapidly become standard of care in my view. Also, critically, the treatment is replicating a natural process that has been shut down by Covid - makes the safety case so much stronger... | bignads | |
22/7/2020 14:27 | It's his own investment not through HG. | tickboo | |
22/7/2020 14:22 | HG focus on technology buyouts, lets see 230p before an approach. dyor | srpactive |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions